{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:33:10Z","timestamp":1793640790247,"version":"4.5.1"},"reference-count":73,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"name":"Cluster of Excellence REBIRTH \u2013 From Regenerative Biology to Reconstructive Therapy"},{"name":"German Research Foundation","award":["DFG-RO 5102\/1-2"],"award-info":[{"award-number":["DFG-RO 5102\/1-2"]}],"id":[{"id":"https:\/\/ror.org\/018mejw64","id-type":"ROR","asserted-by":"crossref"}]},{"name":"European Union\u2019s Horizon 2020 research and innovation program","award":["n\u00b0 755170"],"award-info":[{"award-number":["n\u00b0 755170"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2026,11,2]]},"DOI":"10.1080\/14712598.2026.2753949","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T16:42:10Z","timestamp":1792773730000},"page":"1197-1207","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["An evaluation of marnetegragene autotemcel for the treatment of severe leukocyte adhesion deficiency type I"],"prefix":"10.1080","volume":"26","author":[{"given":"Jenni","family":"Fleischauer","sequence":"first","affiliation":[{"name":"Hannover Medical School","place":["Hannover, Germany"]},{"name":"Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Rothe","sequence":"additional","affiliation":[{"name":"Hannover Medical School","place":["Hannover, Germany"]},{"name":"Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng Cheong","family":"Ha","sequence":"additional","affiliation":[{"name":"Hannover Medical School","place":["Hannover, Germany"]},{"name":"Hannover Medical School","place":["Hannover, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Schambach","sequence":"additional","affiliation":[{"name":"Hannover Medical School","place":["Hannover, Germany"]},{"name":"Hannover Medical School","place":["Hannover, Germany"]},{"name":"Dana-Farber Cancer Institute, Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,11,1]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1006\/BCMD.2001.0473"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2007.00590.x"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13312-012-0005-9"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00971-6"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.5114\/ceji.2014.43725"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.HOC.2012.10.001"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.JAIP.2017.12.008"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002185"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2025.2538543"},{"issue":"1","key":"e_1_3_4_12_1","first-page":"39","article-title":"Leukocyte adhesion deficiency: molecular basis and functional consequences","volume":"1","author":"Fischer A","year":"1988","unstructured":"Fischer A, Lisowska-Grospierre B, Anderson DC. Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodefic Rev. 1988;1(1):39\u201354. PubMed PMID: 3078709.","journal-title":"Immunodefic Rev"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1612197"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30021-3"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502754"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0735-5"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-688226"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2113206"},{"key":"e_1_3_4_19_1","unstructured":"U.S. Food and Drug Administration. FDA approves first gene therapies to treat patients with sickle cell disease. Available from FDA News release [Internet]. 2023 [cited 2026 Sep 16]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease"},{"key":"e_1_3_4_20_1","unstructured":"U.S. Food and Drug Administration. FDA approves first gene therapy for children with metachromatic leukodystrophy. Available from FDA News release [Internet]. 2024 [cited 2026 Sep 16]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-children-metachromatic-leukodystrophy"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.288.5466.669"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35700"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1393"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.12.009"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405541"},{"key":"e_1_3_4_26_1","unstructured":"U.S. Food and Drug Administration. FDA approves first gene therapy for severe leukocyte adhesion deficiency type I [Internet]. 2026 [cited 2026 Jul 21]. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-gene-therapy-severe-leukocyte-adhesion-deficiency-type-i"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2015.141119"},{"key":"e_1_3_4_28_1","unstructured":"World Marrow Donor Association (WMDA). Total number of donors and cord blood units. Available from cited 2026 Jun 9]. Available from: https:\/\/statistics.wmda.info\/"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/695018"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-828277"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.2450\/2012.0106-11"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701131"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702996"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007280"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddz170"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.02.020"},{"key":"e_1_3_4_37_1","volume-title":"Ustekinumab","author":"Colquhoun KA","year":"2026","unstructured":"Colquhoun KA. Ustekinumab. Treasure Island, Florida (FL), USA: StatPearls Publishing; 2026."},{"key":"e_1_3_4_38_1","unstructured":"Stewart J. Stelara FDA approval history. Available from cited 2026 Jun 9]. Available from: https:\/\/www.drugs.com\/history\/stelara.html"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2407376"},{"key":"e_1_3_4_40_1","unstructured":"Rocket Pharmaceuticals Inc. Package Insert - KRESLADI [Internet]. U.S. Food and Drug Administration (FDA); 2026 [cited 2026 Jul 21]. Available from: https:\/\/www.fda.gov\/media\/191722\/download"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj1550273"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.141.4.709"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.9.5940"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2008.10.001"},{"issue":"7","key":"e_1_3_4_45_1","first-page":"931","article-title":"The fps\/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network","volume":"7","author":"Haigh J","year":"1996","unstructured":"Haigh J, McVeigh J, Greer P. The fps\/fes tyrosine kinase is expressed in myeloid, vascular endothelial, epithelial, and neuronal cells and is localized in the trans-golgi network. Cell Growth Differ. 1996;7(7):931\u2013944.","journal-title":"Cell Growth Differ"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.22.6.1903-1918.2002"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.226"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2017.245"},{"key":"e_1_3_4_49_1","unstructured":"Press Release. Orchard therapeutics extends runway into 2024 focusing HSC gene therapy platform exclusively on severe neurometabolic diseases and research platform. Orchard Therapeutics. 2022. [accessed 2026 Oct 26]. Available from: https:\/\/ir.orchard-tx.com\/news-releases\/news-release-details\/orchard-therapeutics-extends-runway-2024-focusing-hsc-gene\/."},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2016.016"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn2401"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2025.03.061"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-021-01110-3"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.04.002"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adn1902"},{"key":"e_1_3_4_56_1","unstructured":"Medically reviewed by Leigh Ann Anderson. 10 of the most expensive drugs in the U.S. 2025 [cited 2026 Jun 10]. Available from: https:\/\/www.drugs.com\/article\/top-10-most-expensive-drugs.html"},{"key":"e_1_3_4_57_1","volume-title":"Morgan Stanley 24th Annual GlobalHealthcare Conference;","author":"Shah G","year":"2026","unstructured":"Shah G. Rocket Pharmaceuticals, Inc. (RCKT) presents at Morgan Stanley 24th annual global healthcare conference transcript. In: Morgan Stanley 24th Annual GlobalHealthcare Conference; New York, NY, USA. Rocket Pharmaceuticals, Inc; 2026."},{"key":"e_1_3_4_58_1","unstructured":"Pagliarulo N. With $2.8M gene therapy Bluebird sets new bar for US drug pricing. Available from BIOPHARMA DIVE [Internet]. 2022 [cited 2026 Sep 24]. Available from: https:\/\/www.biopharmadive.com\/news\/bluebird-bio-gene-therapy-price-zynteglo-million\/629967\/"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/d43978-023-00145-1"},{"key":"e_1_3_4_60_1","unstructured":"Editas Medicine. Editas medicine announces strategic updates and portfolio reprioritization [Internet]. 2023 [cited 2026 Sep 18]. Available from: https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-strategic-updates-and-portfolio"},{"key":"e_1_3_4_61_1","unstructured":"Editas Medicine. Editas medicine announces clinical data demonstrating proof of concept of EDIT-101 from phase 1\/2 brilliance trial [Internet]. 2022 [cited 2026 Sep 18]. Available from: https:\/\/ir.editasmedicine.com\/news-releases\/news-release-details\/editas-medicine-announces-clinical-data-demonstrating-proof"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.13998"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2020.1779886"},{"key":"e_1_3_4_64_1","unstructured":"Ju JH Juenemann R Methven Jeknic S et al. Unlocking the feasibility of rare disease drug development insights from quantitative systems modeling [Internet]. BridgeBio Pharma Inc; 2025 [cited 2026 Sep 18]. Available from: https:\/\/bridgebio.com\/insights\/unlocking-the-feasibility-of-rare-disease-drug-development"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1715536"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.2217\/rme-2020-0169"},{"key":"e_1_3_4_67_1","unstructured":"uniQure. uniQure announces it will not seek marketing authorization renewal for glybera in Europe [Internet]. 2017 [cited 2026 Jun 10]. Available from: https:\/\/uniqure.gcs-web.com\/news-releases\/news-release-details\/uniqure-announces-it-will-not-seek-marketing-authorization"},{"key":"e_1_3_4_68_1","unstructured":"BioMarin. BioMarin voluntarily withdraws ROCTAVIAN\u00ae (valoctocogene roxaparvovec-rvox) from the market [Internet]. 2026 [cited 2026 Jun 10]. Available from: https:\/\/www.biomarin.com\/news\/company-statements\/biomarin-voluntarily-withdraws-roctavian-from-the-market\/"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-024-03492-4"},{"key":"e_1_3_4_70_1","unstructured":"Runken MC Noone JM Blanchette CM et al. Differences in patient demographics and healthcare costs of patients with PIDD receiving intravenous or subcutaneous immunoglobulin therapies in the United States. 2019."},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108359"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s41669-025-00594-y"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-025-00207-7"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01934-9"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02208-8"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2753949","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14712598.2026.2753949","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2026.2753949","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:23:07Z","timestamp":1793640187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2026.2753949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,1]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11,2]]}},"alternative-id":["10.1080\/14712598.2026.2753949"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2026.2753949","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,11,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-11-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}